Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 14 studies | 28% ± 8% | |
lung | 12 studies | 30% ± 14% | |
kidney | 8 studies | 22% ± 5% | |
intestine | 8 studies | 24% ± 11% | |
eye | 7 studies | 25% ± 12% | |
brain | 7 studies | 36% ± 12% | |
uterus | 5 studies | 26% ± 12% | |
lymph node | 5 studies | 23% ± 3% | |
placenta | 4 studies | 26% ± 13% | |
bone marrow | 4 studies | 20% ± 3% | |
prostate | 4 studies | 26% ± 9% | |
breast | 4 studies | 24% ± 3% | |
liver | 4 studies | 35% ± 20% | |
pancreas | 3 studies | 50% ± 2% | |
thymus | 3 studies | 41% ± 18% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
bladder | 100% | 3369.48 | 21 / 21 | 100% | 59.36 | 504 / 504 |
breast | 100% | 3225.98 | 459 / 459 | 100% | 62.14 | 1118 / 1118 |
esophagus | 100% | 3585.11 | 1445 / 1445 | 100% | 45.33 | 183 / 183 |
ovary | 100% | 2769.67 | 180 / 180 | 100% | 52.20 | 430 / 430 |
prostate | 100% | 3581.62 | 245 / 245 | 100% | 69.24 | 502 / 502 |
skin | 100% | 4121.47 | 1809 / 1809 | 100% | 48.82 | 472 / 472 |
uterus | 100% | 3391.83 | 170 / 170 | 100% | 56.09 | 459 / 459 |
brain | 100% | 4634.22 | 2638 / 2642 | 100% | 63.88 | 705 / 705 |
lung | 100% | 3391.94 | 577 / 578 | 100% | 54.04 | 1155 / 1155 |
kidney | 100% | 3373.01 | 89 / 89 | 100% | 39.24 | 898 / 901 |
stomach | 100% | 2501.80 | 359 / 359 | 100% | 55.06 | 285 / 286 |
intestine | 100% | 3388.91 | 966 / 966 | 100% | 58.51 | 525 / 527 |
thymus | 100% | 2849.32 | 652 / 653 | 99% | 36.26 | 601 / 605 |
adrenal gland | 100% | 3727.90 | 258 / 258 | 99% | 47.51 | 227 / 230 |
liver | 100% | 1682.08 | 226 / 226 | 98% | 23.98 | 399 / 406 |
pancreas | 96% | 1367.54 | 316 / 328 | 99% | 39.01 | 176 / 178 |
adipose | 100% | 3405.61 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 79.56 | 29 / 29 |
muscle | 100% | 2824.50 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 3450.27 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 48.78 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 48.54 | 1 / 1 |
blood vessel | 100% | 3670.37 | 1332 / 1335 | 0% | 0 | 0 / 0 |
heart | 98% | 2849.03 | 841 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 95% | 32.23 | 76 / 80 |
peripheral blood | 86% | 3467.80 | 799 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0016567 | Biological process | protein ubiquitination |
GO_1902523 | Biological process | positive regulation of protein K63-linked ubiquitination |
GO_0045739 | Biological process | positive regulation of DNA repair |
GO_0006282 | Biological process | regulation of DNA repair |
GO_1902533 | Biological process | positive regulation of intracellular signal transduction |
GO_0006301 | Biological process | postreplication repair |
GO_0050852 | Biological process | T cell receptor signaling pathway |
GO_0000724 | Biological process | double-strand break repair via homologous recombination |
GO_0051092 | Biological process | positive regulation of NF-kappaB transcription factor activity |
GO_0000729 | Biological process | DNA double-strand break processing |
GO_0043123 | Biological process | positive regulation of canonical NF-kappaB signal transduction |
GO_0070534 | Biological process | protein K63-linked ubiquitination |
GO_2000781 | Biological process | positive regulation of double-strand break repair |
GO_1904262 | Biological process | negative regulation of TORC1 signaling |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0140374 | Biological process | antiviral innate immune response |
GO_0000151 | Cellular component | ubiquitin ligase complex |
GO_0070062 | Cellular component | extracellular exosome |
GO_0032991 | Cellular component | protein-containing complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0031371 | Cellular component | ubiquitin conjugating enzyme complex |
GO_0005737 | Cellular component | cytoplasm |
GO_0031372 | Cellular component | UBC13-MMS2 complex |
GO_0005634 | Cellular component | nucleus |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0005524 | Molecular function | ATP binding |
GO_0003723 | Molecular function | RNA binding |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0061631 | Molecular function | ubiquitin conjugating enzyme activity |
GO_0097027 | Molecular function | ubiquitin-protein transferase activator activity |
GO_0005515 | Molecular function | protein binding |
GO_0043130 | Molecular function | ubiquitin binding |
Gene name | UBE2N |
Protein name | Ubiquitin-conjugating enzyme E2 N (EC 2.3.2.23) (Bendless-like ubiquitin-conjugating enzyme) (E2 ubiquitin-conjugating enzyme N) (Ubc13) (UbcH13) (Ubiquitin carrier protein N) (Ubiquitin-protein ligase N) E2 ubiquitin-conjugating enzyme (EC 2.3.2.23) Ubiquitin conjugating enzyme E2 N |
Synonyms | hCG_38950 BLU HEL-S-71 |
Description | FUNCTION: The UBE2V1-UBE2N and UBE2V2-UBE2N heterodimers catalyze the synthesis of non-canonical 'Lys-63'-linked polyubiquitin chains. This type of polyubiquitination does not lead to protein degradation by the proteasome. Mediates transcriptional activation of target genes. Plays a role in the control of progress through the cell cycle and differentiation. Plays a role in the error-free DNA repair pathway and contributes to the survival of cells after DNA damage. Acts together with the E3 ligases, HLTF and SHPRH, in the 'Lys-63'-linked poly-ubiquitination of PCNA upon genotoxic stress, which is required for DNA repair. Appears to act together with E3 ligase RNF5 in the 'Lys-63'-linked polyubiquitination of JKAMP thereby regulating JKAMP function by decreasing its association with components of the proteasome and ERAD. Promotes TRIM5 capsid-specific restriction activity and the UBE2V1-UBE2N heterodimer acts in concert with TRIM5 to generate 'Lys-63'-linked polyubiquitin chains which activate the MAP3K7/TAK1 complex which in turn results in the induction and expression of NF-kappa-B and MAPK-responsive inflammatory genes. Together with RNF135 and UB2V1, catalyzes the viral RNA-dependent 'Lys-63'-linked polyubiquitination of RIGI to activate the downstream signaling pathway that leads to interferon beta production . UBE2V1-UBE2N together with TRAF3IP2 E3 ubiquitin ligase mediate 'Lys-63'-linked polyubiquitination of TRAF6, a component of IL17A-mediated signaling pathway. . |
Accessions | F8VV71 P61088 ENST00000552442.1 ENST00000549833.1 V9HW41 F8VZ29 F8VQQ8 F8VSD4 ENST00000549490.1 ENST00000550657.1 ENST00000318066.7 |